Victory Capital Management Inc. Lowers Position in Artivion, Inc. (NYSE:AORT)

Victory Capital Management Inc. decreased its position in Artivion, Inc. (NYSE:AORT) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 105,769 shares of the company’s stock after selling 1,430 shares during the period. Victory Capital Management Inc.’s holdings in Artivion were worth $3,024,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in AORT. Lord Abbett & CO. LLC purchased a new stake in shares of Artivion in the third quarter valued at about $5,798,000. Tidal Investments LLC boosted its holdings in shares of Artivion by 602.2% in the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock valued at $4,179,000 after acquiring an additional 134,642 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after acquiring an additional 125,668 shares in the last quarter. Sio Capital Management LLC purchased a new stake in shares of Artivion in the third quarter valued at about $3,226,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Artivion by 394.9% in the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock valued at $2,606,000 after purchasing an additional 78,120 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Stock Performance

Shares of AORT opened at $24.15 on Monday. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The stock has a market cap of $1.02 billion, a P/E ratio of -1,207.25 and a beta of 1.79. The company has a 50-day moving average of $28.66 and a two-hundred day moving average of $27.74. Artivion, Inc. has a 12-month low of $19.36 and a 12-month high of $32.33.

Artivion (NYSE:AORT) last announced its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The business had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. As a group, research analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on AORT shares. Stifel Nicolaus reduced their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Finally, Needham & Company LLC reduced their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $31.40.

Insiders Place Their Bets

In other news, SVP Jean F. Holloway sold 18,020 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $425,452.20. Following the completion of the transaction, the senior vice president now owns 197,184 shares of the company’s stock, valued at $4,655,514.24. The trade was a 8.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John E. Davis sold 15,100 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $356,511.00. Following the completion of the transaction, the insider now directly owns 208,778 shares of the company’s stock, valued at approximately $4,929,248.58. This represents a 6.74 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 90,799 shares of company stock worth $2,356,223. Insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.